MedPath

M.D. ANDERSON CANCER CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Early Phase 1
Active, not recruiting
Conditions
Carcinoid Tumor
Digestive System Neuroendocrine Tumor G1
Carcinoid Syndrome
Metastatic Carcinoid Tumor
Interventions
Procedure: Dual-Energy Computed Tomography
First Posted Date
2021-08-06
Last Posted Date
2024-08-21
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
71
Registration Number
NCT04993261
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Feasibility of Mobile-CT-Assisted Bronchoscopy for the Diagnosis of Lung Lesion

Completed
Conditions
Lung Neoplasm
Interventions
Procedure: Computed Tomography
Other: Electronic Health Record Review
Procedure: Endobronchial Ultrasound Bronchoscopy
First Posted Date
2021-08-06
Last Posted Date
2024-12-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
72
Registration Number
NCT04995172
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Phase 1
Recruiting
Conditions
Recurrent Supratentorial Glioblastoma
Supratentorial Gliosarcoma
Recurrent Gliosarcoma
Interventions
Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Procedure: Resection
First Posted Date
2021-08-05
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
25
Registration Number
NCT04991870
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Phase 2
Withdrawn
Conditions
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
Interventions
First Posted Date
2021-08-04
Last Posted Date
2022-03-10
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04990778
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Technology-Enhanced Palliative Care for Advanced Cancer Patients

Not Applicable
Active, not recruiting
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Other: Interview
Other: Palliative Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2021-08-04
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
119
Registration Number
NCT04989556
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Recruiting
Conditions
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Melanoma, Stage II
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Melanoma Stage IV
Interventions
Behavioral: Assessment
Procedure: Biospecimen Collection
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2021-08-04
Last Posted Date
2024-08-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
275
Registration Number
NCT04990726
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

Phase 2
Withdrawn
Conditions
Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Metastatic Malignant Neoplasm in the Lung
Interventions
Procedure: Computed Tomography
Drug: Indocyanine Green Solution
Device: Therapeutic Bronchoscopy
First Posted Date
2021-08-03
Last Posted Date
2024-10-23
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04987281
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

Recruiting
Conditions
Central Nervous System Neoplasm
Primary Brain Neoplasm
Leptomeningeal Neoplasm
Metastatic Malignant Neoplasm in the Brain
Interventions
Other: Electronic Health Record Review
Other: Survey Administration
First Posted Date
2021-08-03
Last Posted Date
2024-03-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
200
Registration Number
NCT04988009
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

Not Applicable
Active, not recruiting
Conditions
Prostate Adenocarcinoma
Stage I Prostate Cancer AJCC v8
Stage II Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Interventions
Other: Dietary Intervention
Procedure: Radical Prostatectomy
First Posted Date
2021-08-02
Last Posted Date
2024-10-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
12
Registration Number
NCT04985565
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Phase 2
Completed
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Interventions
First Posted Date
2021-07-30
Last Posted Date
2024-11-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
100
Registration Number
NCT04983901
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath